邓蓉 - 中山大学 - 肿瘤防治中心

个人简介

1998年毕业于衡阳医学院临床医学系，2009年于中山大学肿瘤防治中心获医学博士学位，2013年- 2015年在美国MD Anderson Cancer Center肿瘤生物学系主任Dr. Mien-Chie Hung实验室从事博士后研究。广东省药理学会肿瘤药理专业委员会委员。2007年荣获第十一届中国药理学“会SERVIER青年药理学工作者奖”。先后主持国家自然科学基金（2项）、广东省自然科学基金（3项）、广东省医学科研基金、中山大学青年基金，作为主要研究人员参与多项973计划，广东省自然科学基金重点项目的研究。在SCI收录期刊上发表论文30余篇，其中第一作者/共同第一作者/通讯作者论文10余篇，包括Oncogene (2篇), Mol Cancer Ther (2篇), Mol Pharmacol等杂志。

研究领域

(1)肿瘤信号转导通路及其靶向药物研究；(2)自噬在肿瘤发生发展中的作用。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

① Deng R# , Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX , Zhu XF. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene. 30: 944-55, 2011. (IF:8.459)　　② Deng R#, Li W, Guan Z, Zhou JM, Wang Y, Mei YP, Li MT, Feng GK, Huang W, Liu ZC, Han Y, Zeng YX, Zhu XF. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene. 25 (53):7070-7, 2006. (IF:8.459)　　③ Deng R#, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 8 (4) :873-882, 2009. (IF:5.68)　　④ Zhou WJ#, Deng R#, Zhang XY, Feng GK, Gu LQ, Zhu XF. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 8 :3203-3213, 2009. (IF:5.68)　　⑤Deng R#, Tang J, Xie BF, Feng GK, Huang YH, Liu ZC, Zhu XF. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 127(1):220-9, 2010. (IF:5.085)　　⑥ Yang F#, Deng R#, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF*. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 5:e1114(1-12), 2014. (IF:5.014)　　⑦Juan Qin#, Jiao Ji#, Rong Deng #, Jun Tang, Fen Yang, Gong-Kan Feng, Wen-Dan Chen, Xiao-Qi Wu, Xiao-Jun Qian, Ke Ding, Xiao-Feng Zhu. DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2. Oncotarget, 30;6(9):6944-58,2015. （IF=6.359）　　⑧Deng R#, Yang F#, Chang SH, Tang J, Qin J, Feng GK, Ding K, Zhu XF*. DC120, a Novel and Potent Inhibitor of AKT Kinase, Induces Tumor Cell Apoptosis and Suppresses Tumor Growth. Mol Pharmacol. 82(2):189-98, 2012. (IF:4.128)　　⑨Tang J#, Deng R#, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH, Zhu XF*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 134 (2) :549-60, 2012.　　⑩ Qin J, Tang J, Jiao L, Ji J, Chen WD, Feng GK, Gao YH, Zhu XF, Deng R*. A diterpenoid compound, excisanin A, inhibits the invasive behavior of breast cancer cells by modulating the integrin β1/FAK/ PI3K/AKT/β-catenin signaling. Life Sci. 93 (18- 19):655-63, 2013.